Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
New Strong Buy Stocks for January 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
by Zacks Equity Research
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
5 Top Stocks That Popped in 2020 and Have Strong Upside Left
by Nalak Das
It seems that Wall Street bulls have no intention of taking a breather after completing the best year in the last six years.
Invest in These 5 Stocks With Solid Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Elanco (ELAN) Surges: Stock Moves 5.3% Higher
by Zacks Equity Research
Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
3 Reasons Growth Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Invest in These 5 Low Leverage Stocks Before Q4 Earnings
by Zacks Equity Research
Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.
Job Additions Top 2 Million Mark Again in 2019: 5 Winners
by Zacks Equity Research
In 2019, 2.1 million employees were added. Here are five stocks that can benefit the most from healthy job additions from the top-gaining sectors.
These 5 Stocks Boast Impressive Interest Coverage Ratio
by Sumit Singh
A company's creditworthiness depends on how effectively it meets interest obligations. One that is capable of generating earnings well above its interest expense can withstand financial hardships.
Amedisys (AMED) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amedisys (AMED) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amedisys Gains on Favorable Demography, New Hospice Buyouts
by Zacks Equity Research
Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.
Amedisys Completes Asana Hospice Acquisition, Expands Network
by Zacks Equity Research
Amedisys (AMED) closes Asana takeover to strengthen its hospice care network.
7 Impressive Growth Stocks to Buy for 2020
by Debanjana Dey
The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.
Rosy Outlook for Outpatient and Home Healthcare Industry
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and participation in APM.
Cigna to Divest Non-Health Unit, Streamline Operations
by Zacks Equity Research
Cigna (CI) announces sale of its Group Life and Disability business to focus on debt reduction and core business of healthcare.
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
5 Healthcare Stocks to Keep the Winning Streak Alive in 2020
by Sapna Bagaria
Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.
Amedisys (AMED) Benefits From Home Health and Personal Care
by Zacks Equity Research
Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.
Teladoc Adds to its Services With Tailored Nutrition Plans
by Zacks Equity Research
Teladoc (TDOC) enhances its service portfolio with the addition of personalized diet programs.
Amedisys (AMED) Up 24.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Amedisys, PC Connection, NRG and Target
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, PC Connection, NRG and Target
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.